SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to ...

Earlier this year, following successful defense of an Inter Partes Review (IPR) challenge and subsequent appeal proceedings, the United States Patent and Trademark Office formally upheld key claims ...

Nasal spray tech facilitates the delivery of proteins, small-molecule drugs and peptides. Credit: 1777177/Shutterstock. The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal ...

The spray leverages ‘Intravail’ technology, which aids in the absorption of epinephrine by widening the nasal cell gaps. Credit: Marina Demeshko / Shutterstock. ARS Pharmaceuticals has announced the ...

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Neurelis, Inc. ("Company"), today announced a transaction with OrbiMed for the sale of the Company's rights, royalty interests, and related sales milestone ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company, is set to transition into a fully integrated pharmaceutical company by April 1, 2024. The company ...

An ARS Pharmaceuticals nasal spray expected to become the first approved non-injectable version of epinephrine for treating severe allergic reactions has been turned down by the FDA, a decision that ...

Zembrace SymTouch 3mg and Tosymra 10mg are intended to treat adults with acute migraine. Credit: Towfiqu barbhuiya on Unsplash. Tonix Pharmaceuticals and Tonix Medicines have acquired two migraine ...

CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current clinical needs for accessible and convenient treatment ...

neffy intranasal epinephrine. [Image from ARS Pharmaceuticals] ARS Pharmaceuticals announced today that the FDA accepted its new drug application (NDA) for neffy, its intranasal epinephrine. The ...

SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred ...

ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred to as ARS-1), for the emergency treatment ...